New York, June 29, 2026, 05:01 EDT
- Eli Lilly closed Friday at $1,208.12, up 7.13%, after touching $1,215.76.
- The one-day gain added about $75.7 billion in market value using WSJ’s shares-outstanding count.
- The stock was quoted at $1,228.52 in pre-market trade at 4:46 a.m. EDT, within $1.48 of Cantor Fitzgerald’s $1,230 target.
- Lilly’s Friday volume was about 2.6 times its Monday-Thursday average.
At 05:01 EDT, the New York Stock Exchange cash session had not opened. NYSE lists a 9:30 a.m. to 4:00 p.m. ET core session, and its 2026 holiday list shows the next full U.S. market closure is July 3 for Independence Day observed.
Eli Lilly and Company NYSE:LLY starts the week with a cleaner investor problem than most mega-cap drug stocks: the stock has already priced in a lot of good news. Friday’s 7.13% jump pushed Lilly to a record close of $1,208.12, and a 4:46 a.m. EDT pre-market quote showed the shares up another 1.69% at $1,228.52. WSJ data put Friday volume at 7.72 million shares, against a 65-day average of 3.25 million.
The narrow angle is the size of the repricing. Lilly rose $80.43 on Friday. Using WSJ’s 941.74 million shares outstanding, that single-session gain was worth about $75.7 billion, or roughly 54% of Pfizer Inc.’s NYSE:PFE current market value of $139.2 billion.
| Measure | Latest read |
|---|---|
| Friday close | $1,208.12 |
| Friday change | +$80.43 / +7.13% |
| Friday intraday high | $1,215.76 |
| Friday volume | 7.72 mln shares |
| 65-day average volume | 3.25 mln shares |
| Estimated one-day value added | $75.7 bln |
| Pre-market quote, 4:46 a.m. EDT | $1,228.52 |
That is a heavy move for a company already valued by WSJ at $1.14 trillion. It matters because a smaller pipeline item, not a new obesity sales print, was enough to pull more capital into the stock while the main U.S. indexes fell.
Lilly said on Friday that the European Medicines Agency’s CHMP backed Jaypirca, its BTK inhibitor, for adult chronic lymphocytic leukemia across all therapy lines. The European Commission decision is expected in one to two months, and Lilly said it has also sent the same data to the U.S. Food and Drug Administration, with a decision expected in the second half of 2026.
The EMA notice was more clipped: CHMP adopted a positive opinion on June 25 for a change to Jaypirca’s marketing authorisation, with the new monotherapy indication for adult CLL patients.
Paolo Ghia, a professor at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele in Milan, said the trial data could “make a meaningful difference.” Jacob Van Naarden, Lilly Oncology president, called Jaypirca a “meaningful new option.” Eli Lilly and Company
The tape shows how far the bid spread. Lilly’s own price lookup shows the stock rose from $1,102.08 on June 22 to $1,208.12 on June 26, a 9.6% gain over the five listed trading days. Friday volume was 7.72 million shares, versus a Monday-Thursday average of about 3.00 million.
| Lilly five-day tape | Close | Volume |
|---|---|---|
| June 22 | $1,102.08 | 3.01 mln |
| June 23 | $1,107.08 | 3.31 mln |
| June 24 | $1,117.26 | 2.91 mln |
| June 25 | $1,127.69 | 2.76 mln |
| June 26 | $1,208.12 | 7.72 mln |
| Mon-Fri change | +9.6% | — |
| Friday vs Mon-Thu volume | — | 2.6x |
The contrast with the wider tape was sharp. Reuters said the S&P 500 (INDEXSP:.INX) fell 0.05% Friday and lost 2.05% for the week. The Nasdaq Composite (INDEXNASDAQ:.IXIC) fell 0.24% Friday and 4.7% for the week, while the PHLX chip index lost 7.9%.
| Friday / week comparison | Performance |
|---|---|
| Lilly, Friday | +7.13% |
| WSJ Health Care/Life Sciences, Friday | +5.55% |
| S&P 500, Friday | -0.05% |
| Nasdaq Composite, Friday | -0.24% |
| S&P 500, week | -2.05% |
| Nasdaq Composite, week | -4.7% |
| PHLX chip index, week | -7.9% |
Associated Press tied Lilly’s 7.1% jump to European regulatory support for medicines including one for Lilly, while noting AI-linked stocks were the drag on the broader market.
The next investor test is less about the cancer drug’s revenue alone and more about valuation support. Investing.com reported that Cantor Fitzgerald reiterated an Overweight rating and a $1,230 target after the Jaypirca news, while BMO Capital kept an Outperform rating. Lilly’s pre-market quote was already within 0.1% of Cantor’s target.
The obesity case still sits under the stock. Reuters reported last week that Lilly expects its weight-loss pill to launch in Europe and Britain in the second half of 2026 or early 2027, with Patrik Jonsson, head of Lilly’s international business, saying the company’s goal remains “public coverage, wherever possible.” Reuters
Reuters also reported that orforglipron could launch in China from late 2026 to early 2027, according to Jonsson, and that first-quarter GLP-1 sales through major Chinese e-commerce platforms Alibaba and JD.com were about 1.4 billion yuan, or $207 million, according to Jefferies.
Related articles: NYSE:LLY
